Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia
- Conditions
- Ataxia Telangiectasia
- Interventions
- Other: Placebo
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Intrabio Limited
- Target Recruit Count
- 45
- Registration Number
- 2024-517706-29-00
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The University of Texas Health (UT Health), Houston, Texas, United States
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
- Conditions
- Niemann-Pick Disease, Type C
- Interventions
- Other: Placebo
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- IntraBio Inc
- Target Recruit Count
- 53
- Registration Number
- NCT05163288
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇦🇺The Royal Melbourne Hospital, Parkville, Victoria, Australia
🇨🇿First Faculty of Medicine, Charles University Hospital Prague, Praha, Czechia
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
- Conditions
- Ataxia TelangiectasiaLouis Bar Syndrome
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- IntraBio Inc
- Target Recruit Count
- 39
- Registration Number
- NCT03759678
- Locations
- 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇩🇪University of Giessen, Gießen, Germany
🇩🇪Ludwig Maximilian University of Munich, München, Germany
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
- Conditions
- Sandhoff DiseaseGM2 GangliosidosisTay-Sachs Disease
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- IntraBio Inc
- Target Recruit Count
- 30
- Registration Number
- NCT03759665
- Locations
- 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸NYU Langone School of Medicine, New York, New York, United States
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- IntraBio Inc
- Target Recruit Count
- 33
- Registration Number
- NCT03759639
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇩🇪University of Giessen, Gießen, Germany
🇩🇪Ludwig Maximilian University of Munich, München, Germany
News
IntraBio Completes Over-Enrollment for Pivotal Niemann-Pick Disease Type C Trial, Data Expected Q2 2023
IntraBio successfully completed recruitment for its Phase III pivotal trial of IB1001 (N-Acetyl-L-Leucine) for Niemann-Pick disease type C, enrolling 130% of target patients across 13 international sites.